Head and Neck Cancer Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)
Description
The head and neck cancer market was valued at USD 3.76 Billion in 2024 , driven by the rising cases of head and neck cancer across 8 major markets. The market is anticipated to grow at a CAGR of 7.40% during the forecast period of 2025-2034, with the values likely to reach USD 7.68 Billion by 2034 .
Head and Neck Cancer Market Overview
Head and neck cancer (HNC) starts in squamous cells that cover mucosal surfaces of the head and neck, such as the mouth, throat, larynx, sinuses, and nasal cavity. Primary categories include cancers of the mouth, throat (nose, mouth, and lower throat), voice box, nasal passages and sinuses, and saliva-producing glands. They affect regions such as lips, gums, throat, voice box, nose, sinuses, and salivary glands. The process of identifying head and neck cancers includes physical examinations, imaging tests, and taking tissue samples for analysis.
Factors that increase risk include using tobacco, drinking alcohol, and being infected with human papillomavirus (HPV). Signs may consist of a continual throat ache, trouble swallowing, loss of voice, and inexplicable bumps. Timely identification is important for improved results, as treatment choices depend on the location and stage of the cancer. Typically, treatment for head and neck cancer includes surgery, radiation, chemotherapy, targeted therapy, and immunotherapy. The choice of treatment depends on the location of the tumor, its stage, the patient's health, and the characteristics of the tumor. Surgery eliminates tumors, then radiation is used to destroy any remaining cancer cells. Chemotherapy and radiation may be combined in more advanced cases. New possibilities for treating advanced or recurrent cases include targeted therapy and immunotherapy.
Head and Neck Cancer Market Growth Drivers
Increasing Alcohol Consumption Spurs Market Growth
The rising consumption of alcohol plays a significant role in advancing the disease prevalence. The National Survey on Drug Use and Health 2023 found that 224.3 million people aged 12 and older in the United States reported drinking alcohol at some point in their lifetime. This included 111.1 million males and 113.2 million females aged 12 and older. Among youth aged 12 to 17, 5.6 million reported drinking alcohol, with 2.5 million boys and 3.1 million girls in this age group. 218.7 million adults aged 18 and older reported alcohol use, with 108.6 million men and 110.1 million women in this age group. The combination of alcohol and smoking greatly increases the risk of oral, pharyngeal, laryngeal, and esophageal cancers. Even though there have been attempts to educate people about the connection between alcohol and cancer and encourage moderation in drinking, there is still a persistent issue of excessive alcohol consumption leading to an increase in new cancer diagnoses.
Rising Prevalence of Head and Neck Cancer
According to NHS, around 12,400 new cases of head and neck cancer are diagnosed in the United Kingdom annually. The National Cancer Institute estimates that in the United States, approximately 71,100 people will be diagnosed with oral cavity, pharynx, or larynx cancer by the end of 2024, with about 16,110 expected to die from these diseases. The disease prevalence is also expanding because of lifestyle choices such as smoking, and drinking.
Head and Neck Cancer Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Growing Adoption of Immune Therapeutics
The emergence of immune therapeutics is changing the way head and neck cancer is treated. Checkpoint inhibitors and other immunotherapies have the potential to improve results for patients with advanced disease, as they enhance the immune system to attack and remove cancer cells. These therapies are more frequently being added to treatment plans, enhancing both the survival rates and quality of life for patients who have exhausted alternative options. Continuing studies and experiments are projected to increase the use of immunotherapy in this type of cancer, leading to market expansion.
Rising R&D Initiatives and Approvals in Cancer Drugs to Boost Head and Neck Cancer Market Value
Innovations in the pharmaceutical industry are being fueled by research and development of cancer drugs, with a focus on head and neck cancer. Companies are concentrating on creating novel treatments with improved effectiveness and safety characteristics, like EGFR inhibitors and immune checkpoint inhibitors. These developments are resulting in the authorization of innovative therapies for advanced head and neck cancers. Research is also investigating the use of a combination of new drugs and traditional treatments in clinical trials, with regulatory agencies fast-tracking approvals for effective drugs to speed up market growth. The focus on innovation is predicted to result in the creation of additional treatment choices tailored to individuals, enhancing patient results, and boosting market expansion.
Adoption of Minimally Invasive Surgeries to Impact Head and Neck Cancer Market Size
Minimally invasive surgery is gaining more popularity in the treatment of head and neck cancer due to its ability to decrease recovery time, preserve functionality, and minimize cosmetic impacts. Techniques such as transoral robotic surgery (TORS) and endoscopic laser surgery allow for the accurate removal of tumors while safeguarding surrounding healthy tissue. This method is advantageous for cancers in the early stages, offering improved outcomes and fewer adverse effects compared to conventional surgery. Enhanced surgical technology is leading to the increased use of MIS in the treatment of head and neck cancer, improving patient care and expanding the market.
Government Initiatives and Funding to Meet Rising Head and Neck Cancer Market Demand
Government efforts and financial support play a vital role in driving progress in the head and neck cancer industry. Developed nations are allocating resources for prevention, early identification, and treatment initiatives, along with boosting research funding for innovative therapies such as immunotherapies.
Head and Neck Cancer Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type:
Market Segmentation Based on Treatment Type to Witness Growth
Based on the treatment type, the market is divided into chemotherapy, immunotherapy, targeted drug therapy, and others. Chemotherapy is expected to dominate the market for the treatment of head and neck cancer, particularly in cases where surgery is not possible, especially in advanced stages. It is frequently combined with radiation therapy or other systemic treatments and utilized in low- and middle-income countries where newer treatments may not be accessible. Chemotherapy has proved to be successful in reducing tumor size and managing disease advancement.
Head and Neck Cancer Market Analysis by Region
Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India. The United States is expected to dominate the market because of higher disease incidence, robust healthcare system, and ongoing research efforts. A rise in cancers among younger adults is creating a need for innovative treatments such as immunotherapy. The market is being supported by advanced diagnostic techniques and government initiatives, prompting pharmaceutical companies to invest significantly in research.
EU-4 and the United Kingdom are also poised to have a significant market share supported by their healthcare systems are robust, with high demand driven by factors such as HPV and lifestyle, as well as strong screening programs. The EMA is backing the growing use of immunotherapy and targeted therapies. Head & Neck Cancer Specialists and Survivors in the United Kingdom established HANCUK, a charity that aims to assist in decision-making, raise awareness for symptoms and treatment of head and neck cancer, and address treatment inequalities.
Leading Players in the Head and Neck Cancer Market
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding, and investment analysis as well as strategic initiatives by the leading players. The major companies in the market are as follows:
Bristol-Myers Squibb Company
Bristol-Myers Squibb focuses on cancer, immunology, cardiovascular, and fibrotic therapies. They launched a Back-to-Work Guide for Head and Neck Cancer Patients in July 2021, providing legal rights information, solutions for challenges post-treatment, and advice on returning to work. The guide is popular among patients, nurses, oncologists, and carers in the United Kingdom.
Eli and Lilly Company
Eli Lilly, an American pharmaceutical company, offers ERBITUX (cetuximab) in combination with platinum-based chemotherapy for first-line treatment of squamous cell carcinoma of the head and neck. Based on the EXTREME trial data, this regimen shows extended overall survival in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck.
F-Hoffmann-La Roche Ltd
Roche is a biotechnology company providing innovative solutions and drugs for cancer, autoimmune diseases, and other health conditions. They also offer in vitro diagnostics and research novel methods for disease prevention and treatment. A clinical trial is being conducted to compare atezolizumab with placebo for head and neck cancer patients at high risk of recurrence or worsening after initial therapy. The study aims to evaluate the efficacy and safety of atezolizumab as adjuvant therapy.
Merck & Co. Inc.
Merck is a biopharmaceutical company focused on prescription medicines, vaccines, and animal health products. In 2023, Merck and Eisai updated for KEYTRUDA plus LENVIMA in metastatic non-small cell lung cancer. The combination is approved for advanced renal cell carcinoma and certain endometrial cancers. Studies are ongoing for various tumor types, including endometrial carcinoma, hepatocellular carcinoma, RCC, head and neck cancer, gastric cancer, and esophageal cancer.
Other players in the market are AstraZeneca plc, Cumberland Pharmaceuticals Inc., GSK plc, Sanofi, and Takeda Pharmaceutical Company Limited.
Key Questions Answered in the Head and Neck Cancer Market Report
Head and Neck Cancer Therapeutics Market
Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market
Head and Neck Cancer Market Overview
Head and neck cancer (HNC) starts in squamous cells that cover mucosal surfaces of the head and neck, such as the mouth, throat, larynx, sinuses, and nasal cavity. Primary categories include cancers of the mouth, throat (nose, mouth, and lower throat), voice box, nasal passages and sinuses, and saliva-producing glands. They affect regions such as lips, gums, throat, voice box, nose, sinuses, and salivary glands. The process of identifying head and neck cancers includes physical examinations, imaging tests, and taking tissue samples for analysis.
Factors that increase risk include using tobacco, drinking alcohol, and being infected with human papillomavirus (HPV). Signs may consist of a continual throat ache, trouble swallowing, loss of voice, and inexplicable bumps. Timely identification is important for improved results, as treatment choices depend on the location and stage of the cancer. Typically, treatment for head and neck cancer includes surgery, radiation, chemotherapy, targeted therapy, and immunotherapy. The choice of treatment depends on the location of the tumor, its stage, the patient's health, and the characteristics of the tumor. Surgery eliminates tumors, then radiation is used to destroy any remaining cancer cells. Chemotherapy and radiation may be combined in more advanced cases. New possibilities for treating advanced or recurrent cases include targeted therapy and immunotherapy.
Head and Neck Cancer Market Growth Drivers
Increasing Alcohol Consumption Spurs Market Growth
The rising consumption of alcohol plays a significant role in advancing the disease prevalence. The National Survey on Drug Use and Health 2023 found that 224.3 million people aged 12 and older in the United States reported drinking alcohol at some point in their lifetime. This included 111.1 million males and 113.2 million females aged 12 and older. Among youth aged 12 to 17, 5.6 million reported drinking alcohol, with 2.5 million boys and 3.1 million girls in this age group. 218.7 million adults aged 18 and older reported alcohol use, with 108.6 million men and 110.1 million women in this age group. The combination of alcohol and smoking greatly increases the risk of oral, pharyngeal, laryngeal, and esophageal cancers. Even though there have been attempts to educate people about the connection between alcohol and cancer and encourage moderation in drinking, there is still a persistent issue of excessive alcohol consumption leading to an increase in new cancer diagnoses.
Rising Prevalence of Head and Neck Cancer
According to NHS, around 12,400 new cases of head and neck cancer are diagnosed in the United Kingdom annually. The National Cancer Institute estimates that in the United States, approximately 71,100 people will be diagnosed with oral cavity, pharynx, or larynx cancer by the end of 2024, with about 16,110 expected to die from these diseases. The disease prevalence is also expanding because of lifestyle choices such as smoking, and drinking.
Head and Neck Cancer Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Growing Adoption of Immune Therapeutics
The emergence of immune therapeutics is changing the way head and neck cancer is treated. Checkpoint inhibitors and other immunotherapies have the potential to improve results for patients with advanced disease, as they enhance the immune system to attack and remove cancer cells. These therapies are more frequently being added to treatment plans, enhancing both the survival rates and quality of life for patients who have exhausted alternative options. Continuing studies and experiments are projected to increase the use of immunotherapy in this type of cancer, leading to market expansion.
Rising R&D Initiatives and Approvals in Cancer Drugs to Boost Head and Neck Cancer Market Value
Innovations in the pharmaceutical industry are being fueled by research and development of cancer drugs, with a focus on head and neck cancer. Companies are concentrating on creating novel treatments with improved effectiveness and safety characteristics, like EGFR inhibitors and immune checkpoint inhibitors. These developments are resulting in the authorization of innovative therapies for advanced head and neck cancers. Research is also investigating the use of a combination of new drugs and traditional treatments in clinical trials, with regulatory agencies fast-tracking approvals for effective drugs to speed up market growth. The focus on innovation is predicted to result in the creation of additional treatment choices tailored to individuals, enhancing patient results, and boosting market expansion.
Adoption of Minimally Invasive Surgeries to Impact Head and Neck Cancer Market Size
Minimally invasive surgery is gaining more popularity in the treatment of head and neck cancer due to its ability to decrease recovery time, preserve functionality, and minimize cosmetic impacts. Techniques such as transoral robotic surgery (TORS) and endoscopic laser surgery allow for the accurate removal of tumors while safeguarding surrounding healthy tissue. This method is advantageous for cancers in the early stages, offering improved outcomes and fewer adverse effects compared to conventional surgery. Enhanced surgical technology is leading to the increased use of MIS in the treatment of head and neck cancer, improving patient care and expanding the market.
Government Initiatives and Funding to Meet Rising Head and Neck Cancer Market Demand
Government efforts and financial support play a vital role in driving progress in the head and neck cancer industry. Developed nations are allocating resources for prevention, early identification, and treatment initiatives, along with boosting research funding for innovative therapies such as immunotherapies.
Head and Neck Cancer Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type:
- Chemotherapy
- Immunotherapy
- Targeted Drug Therapy
- Others
- Oral
- Parenteral
- Others
- Hospitals
- Clinics
- Diagnostic Centers
- Research Laboratories
- Others
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Market Segmentation Based on Treatment Type to Witness Growth
Based on the treatment type, the market is divided into chemotherapy, immunotherapy, targeted drug therapy, and others. Chemotherapy is expected to dominate the market for the treatment of head and neck cancer, particularly in cases where surgery is not possible, especially in advanced stages. It is frequently combined with radiation therapy or other systemic treatments and utilized in low- and middle-income countries where newer treatments may not be accessible. Chemotherapy has proved to be successful in reducing tumor size and managing disease advancement.
Head and Neck Cancer Market Analysis by Region
Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India. The United States is expected to dominate the market because of higher disease incidence, robust healthcare system, and ongoing research efforts. A rise in cancers among younger adults is creating a need for innovative treatments such as immunotherapy. The market is being supported by advanced diagnostic techniques and government initiatives, prompting pharmaceutical companies to invest significantly in research.
EU-4 and the United Kingdom are also poised to have a significant market share supported by their healthcare systems are robust, with high demand driven by factors such as HPV and lifestyle, as well as strong screening programs. The EMA is backing the growing use of immunotherapy and targeted therapies. Head & Neck Cancer Specialists and Survivors in the United Kingdom established HANCUK, a charity that aims to assist in decision-making, raise awareness for symptoms and treatment of head and neck cancer, and address treatment inequalities.
Leading Players in the Head and Neck Cancer Market
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding, and investment analysis as well as strategic initiatives by the leading players. The major companies in the market are as follows:
Bristol-Myers Squibb Company
Bristol-Myers Squibb focuses on cancer, immunology, cardiovascular, and fibrotic therapies. They launched a Back-to-Work Guide for Head and Neck Cancer Patients in July 2021, providing legal rights information, solutions for challenges post-treatment, and advice on returning to work. The guide is popular among patients, nurses, oncologists, and carers in the United Kingdom.
Eli and Lilly Company
Eli Lilly, an American pharmaceutical company, offers ERBITUX (cetuximab) in combination with platinum-based chemotherapy for first-line treatment of squamous cell carcinoma of the head and neck. Based on the EXTREME trial data, this regimen shows extended overall survival in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck.
F-Hoffmann-La Roche Ltd
Roche is a biotechnology company providing innovative solutions and drugs for cancer, autoimmune diseases, and other health conditions. They also offer in vitro diagnostics and research novel methods for disease prevention and treatment. A clinical trial is being conducted to compare atezolizumab with placebo for head and neck cancer patients at high risk of recurrence or worsening after initial therapy. The study aims to evaluate the efficacy and safety of atezolizumab as adjuvant therapy.
Merck & Co. Inc.
Merck is a biopharmaceutical company focused on prescription medicines, vaccines, and animal health products. In 2023, Merck and Eisai updated for KEYTRUDA plus LENVIMA in metastatic non-small cell lung cancer. The combination is approved for advanced renal cell carcinoma and certain endometrial cancers. Studies are ongoing for various tumor types, including endometrial carcinoma, hepatocellular carcinoma, RCC, head and neck cancer, gastric cancer, and esophageal cancer.
Other players in the market are AstraZeneca plc, Cumberland Pharmaceuticals Inc., GSK plc, Sanofi, and Takeda Pharmaceutical Company Limited.
Key Questions Answered in the Head and Neck Cancer Market Report
- What was the head and neck cancer market value in 2024?
- What is the head and neck cancer market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on treatment type?
- What is market segmentation based on the route of administration?
- What are the major factors aiding the head and neck cancer market demand?
- Who are the major end users in the market?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major drivers, opportunities, and restraints in the market?
- What are the major trends influencing the market?
- Which regional market is expected to dominate the market share in the forecast period?
- Which country is likely to experience elevated growth during the forecast period?
- Who are the key players involved in the head and neck cancer market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Head and Neck Cancer Therapeutics Market
Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Head and Neck Cancer Market Overview – 8 Major Markets
- 3.1 Head and Neck Cancer Market Historical Value 2018-2024
- 3.2 Head and Neck Cancer Market Forecast Value 2025-2034
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Head and Neck Cancer Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Head and Neck Cancer Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview 2018-2034
- 7.2 Prevalence, by Country
- 7.2.1 United States
- 7.2.2 United Kingdom
- 7.2.3 EU4
- 7.2.4 India
- 7.2.5 Japan
- 7.3 Diagnosed Cases, by Country
- 7.3.1 United States
- 7.3.2 United Kingdom
- 7.3.3 EU4
- 7.3.4 India
- 7.3.5 Japan
- 7.4 Treatment Seeking Rate, by Country
- 7.4.1 United States
- 7.4.2 United Kingdom
- 7.4.3 EU4
- 7.4.4 India
- 7.4.5 Japan
- 8 Head and Neck Cancer Market Landscape – 8 Major Markets
- 8.1 Head and Neck Cancer Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Head and Neck Cancer Market: Product Landscape
- 8.2.1 Analysis by Treatment Type
- 8.2.2 Analysis by Route of Administration
- 9 Head and Neck Cancer Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Head and Neck Cancer Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Head and Neck Cancer Market Segmentation 218-2034 - 8 Major Markets
- 12.1 Head and Neck Cancer Market 2018-2034 by Treatment Type
- 12.1.1 Market Overview
- 12.1.2 Chemotherapy
- 12.1.3 Immunotherapy
- 12.1.4 Targeted Drug Therapy
- 12.1.5 Others
- 12.2 Head and Neck Cancer Market 2018-2034 by Route of Administration
- 12.2.1 Market Overview
- 12.2.2 Oral
- 12.2.3 Parenteral
- 12.2.4 Others
- 12.3 Head and Neck Cancer Market 2018-2034 by End User
- 12.3.1 Market Overview
- 12.3.2 Hospitals
- 12.3.3 Clinics
- 12.3.4 Diagnostic Centers
- 12.3.5 Research Laboratories
- 12.3.6 Others
- 12.4 Head and Neck Cancer Market 2018-2034 by Region
- 12.4.1 Market Overview
- 12.4.2 United States
- 12.4.3 EU-4 and the United Kingdom
- 12.4.3.1 Germany
- 12.4.3.2 France
- 12.4.3.3 Italy
- 12.4.3.4 Spain
- 12.4.3.5 United Kingdom
- 12.4.4 Japan
- 12.4.5 India
- 13 United States Head and Neck Cancer Market 218-2034
- 13.1 United States Head and Neck Cancer Market 2018-2034 by Treatment Type
- 13.1.1 Market Overview
- 13.1.2 Chemotherapy
- 13.1.3 Immunotherapy
- 13.1.4 Targeted Drug Therapy
- 13.1.5 Others
- 13.2 United States Head and Neck Cancer Market 2018-2034 by Route of Administration
- 13.2.1 Market Overview
- 13.2.2 Oral
- 13.2.3 Parenteral
- 13.2.4 Others
- 13.3 United States Head and Neck Cancer Market 2018-2034 by End User
- 13.3.1 Market Overview
- 13.3.2 Hospitals
- 13.3.3 Clinics
- 13.3.4 Diagnostic Centers
- 13.3.5 Research Laboratories
- 13.3.6 Others
- 14 EU-4 and United Kingdom Head and Neck Cancer Market 218-2034
- 14.1 EU-4 and United Kingdom Head and Neck Cancer Market 2018-2034 by Treatment Type
- 14.1.1 Market Overview
- 14.1.2 Chemotherapy
- 14.1.3 Immunotherapy
- 14.1.4 Targeted Drug Therapy
- 14.1.5 Others
- 14.2 EU-4 and United Kingdom Head and Neck Cancer Market 2018-2034 by Route of Administration
- 14.2.1 Market Overview
- 14.2.2 Oral
- 14.2.3 Parenteral
- 14.2.4 Others
- 14.3 EU-4 and United Kingdom Head and Neck Cancer Market 2018-2034 by End User
- 14.3.1 Market Overview
- 14.3.2 Hospitals
- 14.3.3 Clinics
- 14.3.4 Diagnostic Centers
- 14.3.5 Research Laboratories
- 14.3.6 Others
- 15 Japan Head and Neck Cancer Market 218-2034
- 15.1 Japan Head and Neck Cancer Market 2018-2034 by Treatment Type
- 15.1.1 Market Overview
- 15.1.2 Chemotherapy
- 15.1.3 Immunotherapy
- 15.1.4 Targeted Drug Therapy
- 15.1.5 Others
- 15.2 Japan Head and Neck Cancer Market 2018-2034 by Route of Administration
- 15.2.1 Market Overview
- 15.2.2 Oral
- 15.2.3 Parenteral
- 15.2.4 Others
- 15.3 Japan Head and Neck Cancer Market 2018-2034 by End User
- 15.3.1 Market Overview
- 15.3.2 Hospitals
- 15.3.3 Clinics
- 15.3.4 Diagnostic Centers
- 15.3.5 Research Laboratories
- 15.3.6 Others
- 16 India Head and Neck Cancer Market 218-2034
- 16.1 India Head and Neck Cancer Market 2018-2034 by Treatment Type
- 16.1.1 Market Overview
- 16.1.2 Chemotherapy
- 16.1.3 Immunotherapy
- 16.1.4 Targeted Drug Therapy
- 16.1.5 Others
- 16.2 India Head and Neck Cancer Market 2018-2034 by Route of Administration
- 16.2.1 Market Overview
- 16.2.2 Oral
- 16.2.3 Parenteral
- 16.2.4 Others
- 16.3 India Head and Neck Cancer Market 2018-2034 by End User
- 16.3.1 Market Overview
- 16.3.2 Hospitals
- 16.3.3 Clinics
- 16.3.4 Diagnostic Centers
- 16.3.5 Research Laboratories
- 16.3.6 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 Japan PMDA
- 17.5 India CDSCO
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 19 Clinical Trials Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grants Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Application
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by NIH Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Drug Class of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Drug Class of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share Analysis, By Region (Top 5 Companies)
- 23.2 Eli Lilly and Company
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Companies News and Developments
- 23.2.5 Certifications
- 23.3 AstraZeneca plc
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Companies News and Developments
- 23.3.5 Certifications
- 23.4 Sanofi S.A.
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Companies News and Developments
- 23.4.5 Certifications
- 23.5 Cumberland Pharmaceuticals Inc.
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Companies News and Developments
- 23.5.5 Certifications
- 23.6 Merck & Co. Inc.
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Companies News and Developments
- 23.6.5 Certifications
- 23.7 Bristol-Myers Squibb Company
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Companies News and Developments
- 23.7.5 Certifications
- 23.8 Takeda Pharmaceutical Company Limited
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Companies News and Developments
- 23.8.5 Certifications
- 23.9 F-Hoffmann-La Roche Ltd
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Companies News and Developments
- 23.9.5 Certifications
- 23.10 GSK plc
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Companies News and Developments
- 23.10.5 Certifications
- 24 Head and Neck Cancer Market - Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
